Startup ReadyCure Secures Pre-A Series Investment from FuturePlay

Developer of Digital X-ray Treatment System Dedicated to Dementia

ReadyCure, a startup developing a digital X-ray treatment system dedicated to dementia, announced on the 10th that it has secured Pre-A series investment from FuturePlay. The investment amount was not disclosed.

Founded in October 2021, ReadyCure is a research lab startup established by CEO Won-kyu Jeong (professor at Gangdong Kyung Hee University Hospital and radiation oncology specialist), brain science researchers, and medical device experts. CEO Jeong is an expert who obtained his specialization in radiation oncology from Jeonbuk National University Graduate School of Medicine and has accumulated 27 years of experience. Based on 7 years of preclinical and clinical research, he founded ReadyCure leveraging his experience in low-dose radiation therapy for dementia patients.

ReadyCure is developing Hellaxon, a dementia treatment system aimed at restoring immune system function in the brain using digital X-rays. This approach is completely different from the methods used in the dementia (cognitive decline) worsening and treatment market, where global big pharma companies are investing astronomical amounts of money to develop antibody therapeutics.

ReadyCure is conducting preclinical studies to evaluate the efficacy of digital X-rays and simultaneously running a large-scale, multi-center, patient-blinded, randomized clinical trial on Alzheimer’s-type dementia patients using cancer treatment devices. CEO Won-kyu Jeong of ReadyCure stated, “If the disease mitigation speed of recently developed dementia drugs was 27%, Hellaxon can alleviate it by up to 80%,” adding, “We will establish a new paradigm in medical practice and bring about innovative changes through the development of a new dementia treatment system that escapes the side effects of drugs.”

Hellaxon image

Guyong Seok, lead investment manager at FuturePlay who led this investment, said, “We decided to invest after highly evaluating the excellent cognitive decline mitigation effects verified through ReadyCure’s researcher clinical results and the research outcomes confirmed in preclinical studies.”

Meanwhile, CEO Jeong is scheduled to present the interim results of the ongoing clinical study at the European Society for Radiotherapy and Oncology (ESTRO) conference held this month in Glasgow, UK.

This content was produced with the assistance of AI translation services.